Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBCBS Michigan Medicare PPO Formulary Coverage Upda…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Currentblue cross blue shield - michiganPolicy N/A

    Medicare Plus Blue PPO 2026 Core Comprehensive Formulary — Prescription Drug Coverage and Utilization Management

    Customize your policy alerts

    Sign up for all blue cross blue shield - michigan policy alerts

    Know when blue cross blue shield - michigan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines the prescription drugs covered under Blue Cross Blue Shield of Michigan's Medicare Plus Blue PPO Core formulary (effective June 1, 2026) including rules on prior authorization, quantity limits, step therapy, exceptions, and transition supplies; affects Medicare Plus Blue PPO members and their prescribers and network pharmacies.

    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyMedicare Plus Blue PPO 2026 Core Comprehensive Formulary
    Policy CodePolicy N/A
    Change TypeAdministrative — annual formulary update (no material clinical changes)
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization and submit supporting clinical documentation when a drug entry is marked 'PA' to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Version 17Formulary version
    06/01/2026Effective date
    31 daysTransition supply
    72 hrsStandard decision timeframe
    24 hrsExpedited decision timeframe
    108 daysSpecial transitional window

    Coverage Rules and Formulary Listings

    Formulary drug coverage

    Covered when ALL of the following are met

    Formulary coverage conditions: Drug is listed on the Medicare Plus Blue PPO formulary; drug is medically necessary; prescription is filled at a Medicare Plus Blue PPO network pharmacy; other plan rules are followed (e.g., prior authorization, quantity limits, step therapy).

    From formulary description

    Transition supply

    Covered when ANY of the following transitional conditions apply

    Transition supply eligibility: Member is new or continuing and taking a drug not on the 2026 formulary or with a new coverage restriction; member is within the first 108 days of membership; or member is a resident of a long-term care facility with limited access and past the first 108 days of membership; plan will cover a temporary supply while an exception or alternative is pursued.31 days
    Policy Summary
    Payerblue cross blue shield - michigan
    PolicyMedicare Plus Blue PPO 2026 Core Comprehensive Formulary
    Policy CodePolicy N/A
    Change TypeAdministrative — annual formulary update (no material clinical changes)
    Effective DateJun 1, 2026
    Last ReviewJun 1, 2026
    Next Review DateN/A
    Key ActionObtain required prior authorization and submit supporting clinical documentation when a drug entry is marked 'PA' to avoid claim denial.
    SourceLink
    On This Page
    Coverage Rules and Formulary ListingsFormulary Listings and Code TablesPrior Authorization, Step Therapy, and Documentation RequirementsStep Therapy Rules and Affected ProductsPer-Product Quantity LimitsInfusion/Administration and Site-Specific NotesFormulary Symbols and Term DefinitionsFormulary Background and ScopeBiosimilar Substitution and Interchangeable Products

    Transition policy: maximum temporary supply = 31 days; plan will send notification within 3 business days when temporary supply is filled.

    Formulary coverage entries

    Coverage and tiering are indicated per drug entry; some entries include quantity limits (QL) or prior authorization (PA).

    Formulary listing: Individual drug entries define Drug Tier and any Requirements/Limits (e.g., QL or PA) that apply to coverage for that product.

    No additional clinical medical-necessity decision logic is provided within these listing rows; refer to individual product rows for QL and PA values.

    Formulary entries with PA and QL

    Coverage and coverage-related requirements are indicated per drug entry via the Requirements/Limits column; examples include:

    PA required entries: Any prescription for a product listed with 'PA' in Requirements/Limits requires prior authorization before coverage; examples in the formulary include l-glutamine packet, nitisinone, PROLASTIN-C, REVCOVI, GENOTROPIN and other growth-modifying or enzyme-replacement products; refer to specific product rows for exact strengths and tiers.

    See individual entries for exact formulations, QL values, and tier assignments.

    Formulary listing and management

    Coverage for listed drugs is expressed by formulary tier and requirement/limit tags. Where 'PA' is present, prior authorization is required; where 'QL' is present, quantity limits apply.

    Formulary entry: Drug is listed with a Tier and may have Requirements/Limits tags (for example: PA, QL, OVM, B/D). Compliance with the listed Requirements/Limits is required for coverage of that specific product.

    This excerpt does not include additional clinical criteria beyond the Requirements/Limits tags; follow the plan's PA and QL processes when those tags are present.

    If a drug is withdrawn from sale by the manufacturer or removed by the FDA for safety or effectiveness reasons, the plan may immediately remove the drug from the formulary. When other changes (for example adding a generic or biosimilar, adding PA/QL/ST, or moving a drug to a different tier) are made that affect members currently taking the drug, the plan will normally provide at least 30 days' notice to affected members or permit a one-time refill of up to a 31-day supply at the time of refill. Members and prescribers retain the right to request a formulary exception when these changes occur.

    The extracted formulary segments do not identify any explicit clinical conditions that would exclude coverage of listed drugs; entries are presented as drug names with tiers and any Requirements/Limits (e.g., QL or PA) but no exclusionary diagnoses are specified in these chunks.

    This section contains product listings with their associated tiers and Requirements/Limits fields (for example QL values shown for multiple formulations and PA indicators where applicable). There are no explicit clinical exclusions noted here—coverage is expressed through the listed drug lines and their Requirements/Limits rather than by named excluded clinical conditions.

    Within these chunks the formulary shows biologic and specialty agents with associated Requirements/Limits (e.g., PA, QL, OVM, B/D). The document segment does not explicitly label any medications as non-covered or excluded; absence of a product from these excerpts should not be interpreted as a non-coverage decision.

    The provided excerpt does not contain any formal 'Not Medically Necessary' determinations. Coverage entries in these chunks are expressed as formulary listings with tiers and utilization controls (PA, QL) rather than NMN statements.

    Not applicable in the examined chunks — there are no explicit 'Not Medically Necessary' (NMN) statements present in this portion of the formulary.

    These chunks do not include any explicit 'Not Medically Necessary' determinations. Formulary rows instead list Requirements/Limits (e.g., QL and PA) and do not state NMN findings in the sampled material.

    Formulary Listings and Code Tables

    Sample formulary drug linesNDC-like/text
    prochlorperazine maleate tablet 10mglisted with Drug Tier = 2
    prochlorperazine suppository 25mglisted with Drug Tier = 4
    promethazine hydrochloride tablet 12.5mg, 25mg, 50mglisted with Drug Tier = 2
    scopolamine patch 72 hour 1mg/3dayslisted with Drug Tier = 4; QL(30 EA per 90 days)
    aprepitant capsule 80mglisted with Drug Tier = 4; B/D or PAK annotations on some entries
    aprepitant capsule 40mglisted with Drug Tier = 4; QL(12 EA per 90 days); B/D
    aprepitant capsule 125mglisted with Drug Tier = 4; QL(6 EA per 90 days); B/D
    dronabinol capsule 10mg, 2.5mg, 5mgTier 4; B/D
    Formulary drug listings (no procedure/diagnosis codes present)mixed
    No codes listed
    Formulary drug entries (selected examples)mixed
    abacavir sulfate/lamivudine 600mg;300mgDrug Tier = 4
    CIMDUO 300mg;300mgDrug Tier = 5
    DESCOVY 120mg;15mg, 200mg;25mgDrug Tier = 5; Requirements/Limits = QL(31 EA per 31 days)
    emtricitabine/tenofovir disoproxil fumarate 200mg;300mgDrug Tier = 3; Requirements/Limits = QL(31 EA per 31 days)
    EMTRIVA SOLUTION 10MG/MLDrug Tier = 4
    ODEFSEY 200MG;25MG;25MGDrug Tier = 5
    TRIUMEQ PD TABLET SOLUBLE 60MG;5MG;30MGDrug Tier = 4; Requirements/Limits = QL(180 EA per 30 days)
    TRIUMEQ TABLET 600MG;50MG;300MGDrug Tier = 5; Requirements/Limits = QL(31 EA per 31 days)
    VIREAD POWDER 40MG/GMDrug Tier = 5
    TROGARZO INJECTION 200MG/1.33MLDrug Tier = 5
    1–10 of 20
    1/2
    Formulary drug entries (no billing codes)mixed
    N/ANo CPT/HCPCS/ICD codes present in this excerpt; only drug names, strengths, tiers and requirement flags are listed.
    Formulary drugs and noted QL/PAmixed
    NEXLETOLNEXLETOL TABLET 180MG (PA; QL(90 EA per 90 days))
    NEXLIZETNEXLIZET TABLET 180MG; 10MG (PA; QL(90 EA per 90 days))
    PRALUENTPRALUENT INJECTION 150MG/ML, 75MG/ML (PA; QL(2 ML per 28 days))
    KERENDIAKERENDIA TABLET 10MG, 20MG, 40MG (PA; QL(90 EA per 90 days))
    CORLANORCORLANOR SOLUTION 5MG/5ML (QL(1350 ML per 90 days))
    ENTRESTOENTRESTO CAPSULE SPRINKLE (QL(720 EA per 90 days))
    ivabradine hydrochlorideivabradine hydrochloride tablet 5mg, 7.5mg (QL(180 EA per 90 days))
    sacubitril/valsartansacubitril/valsartan tablet (QL(180 EA per 90 days))
    fenofibratefenofibrate products (various strengths; QL examples listed)
    Sample listed formulary drugs (non-exhaustive)mixed
    FIRMAGON INJECTION 120MG/VIALDrug listed with Tier = 5; Requirements/Limits = .
    lanreotide acetate injection 120mg/0.5mlDrug Tier = 5; Requirements/Limits = PA
    leuprolide acetate injection 1mg/0.2ml, 22.5mgDrug Tier = 4; Requirements/Limits = PA
    LUPRON DEPOT (1-MONTH) INJECTION 3.75MG, 7.5MGDrug Tier = 5; Requirements/Limits = PA
    Drugs with large-volume QL entriesmixed
    SKYRIZI INJECTION 180MG/1.2ML, 360MG/2.4MLDrug Tier = 5; Requirements/Limits = QL(2.4 ML per 56 days); PA
    STELARA INJECTION 130MG/26MLDrug Tier = 5; Requirements/Limits = QL(208 ML per 365 days); PA
    USTEKINUMAB INJECTION 130MG/26MLDrug Tier = 5; Requirements/Limits = QL(208 ML per 365 days); PA
    Selected immunosuppressants/biologics with QLmixed
    ADALIMUMAB-ADBM INJECTION 40MG/0.4MLDrug Tier = 5; Requirements/Limits = QL(6 EA per 28 days); PA
    ENBREL INJECTION 25MG/0.5MLDrug Tier = 5; Requirements/Limits = QL(16 ML per 28 days); PA
    Formulary utilization codes and limitsmixed
    QL(1080 EA per 90 days)quantity limit as listed for mesalamine DR capsule 400mg
    QL(360 EA per 90 days)quantity limit as listed for mesalamine DR tablet 1.2g
    QL(540 EA per 90 days)quantity limit as listed for mesalamine DR tablet 800mg
    QL(5400 ML per 90 days)quantity limit as listed for mesalamine enema 4gm
    PAprior authorization required (indicator used across multiple products)
    STstep therapy indicator (used for select products)
    B/Dbenefit/dispense restriction indicator (documented for some nebulized/inhaled products)
    OVMOVM/OVM-like notation shown for select products (usage restriction)
    inv-22: Example quantity limits (sample values from various entries)
    Linezolid suspension (reconstituted 100mg/5ml)QL(1680 ML per 28 days)
    Linezolid tablet 600mgQL(56 EA per 28 days)
    VOQUEZNA dual/triple pak therapy packQL(336 EA per 90 days); PA
    inv-23: Examples of quantity limits (specific products and QL values)
    LIBERVANT FILMQL(10 EA per 30 days); PA; NDS
    VALTOCO (all strengths listed)QL(10 EA per 30 days); PA; NDS
    vigabatrin (packet/tablet 500mg)QL(186 EA per 31 days); PA
    inv-24: Quantity limits examples — assorted per-product QLs
    CRESEMBA capsule 74.5mgQL(175 EA per 31 days); PA
    CRESEMBA capsule 186mgQL(70 EA per 31 days); PA
    posaconazole DR tablet 100mgQL(93 EA per 31 days); PA
    inv-25: Representative quantity limits — mixed examples across chunks
    dabigatran etexilate capsuleQL(180 EA per 90 days)
    ELIQUIS starter pack (5mg therapy pack)QL(148 EA per 365 days)
    rivaroxaban suspension (reconstituted 1mg/ml)QL(2700 ML per 90 days)
    inv-26: Quantity Limits examples — exact QL values from listing
    Examples across formulary (common pattern)QL(180 EA per 90 days); QL(360 EA per 90 days); QL(90 EA per 90 days)
    PRALUENT injectionQL(2 ML per 28 days); PA
    CORLANOR solution 5mg/5mlQL(1350 ML per 90 days)
    inv-27: Example quantity limits — dabigatran, rivaroxaban suspension, ELIQUIS starter pack entries
    ELIQUIS tablet soluble 0.5mg (selected entries)QL(1164 EA per 90 days); QL(1552 EA per 90 days); QL(388 EA per 90 days)
    ELIQUIS starter pack 5mg therapy packQL(148 EA per 365 days)
    rivaroxaban suspension reconstituted 1mg/mlQL(2700 ML per 90 days)
    inv-28: Common quantity limit examples across formulary
    QL(180 EA per 90 days) patternCommon across many oral chronic therapies (e.g., multiple cardiovascular and CNS agents)
    QL(360 EA per 90 days) patternAppears for select extended supplies (e.g., some anticonvulsant tablets)
    QL(2 ML per 28 days)Used for several injectable biologics (e.g., PRALUENT)
    inv-29: Quantity Limits examples — assorted entries
    calcipotriene cream 0.005%QL(360 GM per 90 days); PA
    RESTASIS multidose emulsion 0.05%QL(180 ML per 90 days)
    XIFAXAN 550mgQL(93 EA per 31 days)
    inv-30: Examples of quantity limits (QL) — dermatologic and oral agents
    clindamycin phosphate topical (various)QL(225 ML/GM per 90 days) depending on formulation
    mupirocin ointment 2%QL(90 GM per 90 days)
    TYRVAYA solutionQL(8.4 ML per 30 days)
    inv-31: Sample quantity limits shown — assorted QL examples from document
    pantoprazole sodium DR tablet 20/40mgQL(180 EA per 90 days)
    l-glutamine packet 5gmQL(180 EA per 30 days); PA
    nitisinone capsuleQL(24 EA per 90 days); PA
    inv-32: icatibant acetate — QL 27 ML per 30 days
    icatibant acetate injection 30mg/3mlQL(27 ML per 30 days); PA
    icatibant noteListed under Angioedema Agents with specified ML-per-period limit
    coverage implicationClaims exceeding QL may be denied or require PA
    inv-33: COSENTYX 150MG/ML — 8 ML per 28 days
    COSENTYX 150mg/ml (Sensoready pen)QL(8 ML per 28 days); PA
    COSENTYX (other presentations)Alternate QLs listed for other strengths (e.g., 4 ML per 28 days for 75mg)
    Formulary noteLarge-volume biologics use ML-based QLs and often require PA
    inv-34: RINVOQ solution — 360 ML per 30 days
    RINVOQ LQ solution 1mg/mlQL(360 ML per 30 days); PA
    RINVOQ tablet entriesSeparate QL entries exist for extended-release tablets (EA per 31 days)
    Usage noteLarge ML QLs apply to solution formulations
    inv-35: Notable quantity limits (RESTASIS, MIEBO, TYRVAYA examples)
    RESTASIS multidose emulsion 0.05%QL(180 ML per 90 days)
    MIEBO solutionQL(36 ML per 90 days)
    TYRVAYA solutionQL(8.4 ML per 30 days)

    Prior Authorization, Step Therapy, and Documentation Requirements

    Prior Authorization

    Obtain prior authorization or request an exception

    Prior authorization is required for certain drugs; prescribers must obtain approval before dispensing or submit a formulary/ tiering exception request with the prescriber's supporting medical rationale as described in the formulary exception process.

    • If approval is not obtained, Medicare Plus Blue PPO may not cover the drug.
    Prior Authorization

    PA required for VOQUEZNA packs

    Certain listed medications are designated 'PA' and require prior authorization before coverage—examples in this excerpt include VOQUEZNA dual and triple therapy packs which show QL(336 EA per 90 days) and PA.

    • VOQUEZNA Dual Pak and Triple Pak: Requirements/Limits = QL(336 EA per 90 days); PA
    Prior Authorization

    PA required for LIBERVANT FILM, VALTOCO, vigabatrin, rufinamide

    Multiple products list 'PA' in Requirements/Limits; examples include LIBERVANT FILM and VALTOCO which also have quantity limits—prescribers must obtain PA prior to dispensing to avoid denial.

    • LIBERVANT FILM: QL(10 EA per 30 days); PA
    • VALTOCO (all strengths listed): QL(10 EA per 30 days); PA
    • vigabatrin: QL(186 EA per 31 days); PA
    • rufinamide entries: PA (and QL on some strengths)
    Prior Authorization

    Submit PA documentation for drugs marked 'PA'

    Numerous formulary rows are annotated 'PA'—prescribers must submit required prior authorization documentation per the plan for drugs marked PA to secure coverage.

    • Examples across tables show many entries with 'PA' requiring pre-approval before the claim is covered.
    Prior Authorization

    PA required for oncology and specialty oral agents

    Many oncology and specialty oral agents are shown with 'PA' (and often OVM); prescribers must obtain prior authorization prior to dispensing these high-cost agents.

    • Examples: BRUKINSA, CABOMETYX, CALQUENCE, IMBRUVICA, IBRANCE — Requirements/Limits = PA; OVM
    Billing Rule

    Adhere to specified quantity limits (QL)

    Quantity limits (QL) are specified for many products; prescribers and pharmacies must follow the QL when prescribing and dispensing (claims may be denied or require override if QL is exceeded).

    • Example QL values: LORBRENA 25mg = QL(93 EA per 31 days); ROZLYTREK 200mg = QL(93 EA per 31 days)
    • See multiple product lines for exact QL entries (per-product QL must be respected)
    Prior Authorization

    Obtain PA for select products listed with 'PA'

    Multiple other drugs in the formulary are flagged 'PA' in the Requirements/Limits column; prescribers must request prior authorization for those products before dispensing to avoid denial.

    • Examples: FANAPT titration packs (PA), LIVTENCITY (PA), PREVYMIS (PA)
    Documentation Required

    Follow table annotations (PA, ST, QL) when submitting PA

    Table annotations mark some products with 'PA' and others with 'ST' or QL; prescribers must follow the Requirements/Limits shown (e.g., GLP-1 receptor agonists and select antidepressants carry PA or ST annotations).

    • Liraglutide, MOUNJARO, OZEMPIC, RYBELSUS appear with PA in Requirements/Limits
    • EXXUA and TRINTELLIX examples show ST (step therapy) in Requirements/Limits
    Prior Authorization

    PA required for concentrated insulin products

    Concentrated insulin products and other insulin formulations may carry 'PA' in Requirements/Limits; prescribers must obtain prior authorization where shown.

    • HUMULIN R U-500 (CONCENTRATED) INJECTION 500UNIT/ML — Requirements/Limits = PA
    • HUMULIN R U-500 KWIKPEN — Requirements/Limits = PA
    Prior Authorization

    Obtain PA for select cardiovascular/lipid agents

    Certain cardiovascular and lipid agents are labeled 'PA' and/or have QL entries; prescribers must obtain PA for drugs so marked before coverage (examples include NEXLETOL, NEXLIZET, PRALUENT, KERENDIA).

    • NEXLETOL/NEXLIZET entries show PA and QL patterns
    • PRALUENT injection = QL(2 ML per 28 days); PA
    • KERENDIA = QL(90 EA per 90 days); PA
    Prior Authorization

    PA required when 'PA' is listed

    Where 'PA' appears in the Requirements/Limits column, prior authorization is required prior to coverage; prescribers must secure authorization for those listed products to avoid claim denial.

    • Examples in this segment include multiple drugs annotated with PA (NEXLETOL, NEXLIZET, PRALUENT, KERENDIA, VERQUVO, betaseron, fingolimod, glatiramer products)
    Prior Authorization

    PA required for OTEZLA and other listed agents

    A range of agents (including OTEZLA formulations) are labeled 'PA' in Requirements/Limits; prescribers must obtain prior authorization before these products will be covered.

    • OTEZLA XR 75MG — QL(31 EA per 31 days); PA
    • XIFAXAN 550MG — QL(93 EA per 31 days); PA (where listed)
    Prior Authorization

    Request PA for genetic/enzyme disorder and depot products

    Multiple listed products require prior authorization (PA) per their Requirements/Limits; examples include l‑glutamine packet and nitisinone—prescribers must request PA for those items.

    • l‑glutamine packet 5gm = QL(180 EA per 30 days); PA
    • nitisinone capsule = QL(24 EA per 90 days); PA
    • GENOTROPIN, SOMATULINE DEPOT, lanreotide, leuprolide depot items = PA
    Prior Authorization

    PA required for specialty depot and hormonal agents

    Many specialty and hormonal depot agents used in oncology/antagonist therapy are marked 'PA'—prescribers must obtain prior authorization prior to administration or dispensing.

    • Examples: FIRMAGON, lanreotide acetate, leuprolide acetate, ORGOVYX, SOMATULINE DEPOT — Requirements/Limits include PA
    Prior Authorization

    PA required for specified GI and specialty injections

    Some other specified products (e.g., budesonide ER tablet 9mg; JUBBONTI injection) list 'PA' in Requirements/Limits—prescribers must obtain prior authorization where indicated.

    • budesonide ER tablet 9mg = PA
    • JUBBONTI injection = QL(1 ML per 180 days); PA
    Step Therapy

    Step therapy — try preferred agent first or request exception

    Step therapy (ST) may require trying preferred drugs first; prescribers may request an exception by submitting clinical rationale and a supporting statement—plan decisions generally within 72 hours (24 hours if expedited).

    • If the prescriber documents that the preferred alternative is ineffective or causes adverse effects, an exception may be granted.
    • Standard decision timeframe: 72 hours; expedited (fast) decisions: 24 hours when clinically necessary.
    Note

    No actionable content in placeholder chunk

    This chunk reference exists in the inventory but contains no summary details in the extracted brief and therefore does not impose a new provider action.

    Step Therapy

    Follow step therapy for EXXUA and TRINTELLIX

    Some products are explicitly marked 'ST' (step therapy) in Requirements/Limits—examples include EXXUA and TRINTELLIX; prescribers must follow step therapy rules where indicated or request an exception with supporting rationale.

    • EXXUA: Requirements/Limits = QL(...); ST
    • TRINTELLIX: Requirements/Limits = QL(...); ST
    Step Therapy

    Step therapy applies to febuxostat

    Certain products include 'ST' in Requirements/Limits (e.g., febuxostat) indicating step therapy applies; prescribers should document prior trials or submit an exception request if clinically appropriate.

    • febuxostat tablet 40mg, 80mg = QL(90 EA per 90 days); ST
    Step Therapy

    RYTARY formulations include QL and ST requirements

    Some RYTARY entries list both QL and ST in Requirements/Limits—prescribers must comply with step therapy requirements and quantity limits or provide documentation supporting medical necessity.

    • RYTARY extended-release formulations: QL(300–360 EA per 30 days) or QL(360 EA per 30 days); ST
    Step Therapy

    Step therapy applies to select antipsychotics and LAIs

    Selected antipsychotics and long-acting injectables are designated with 'ST' in Requirements/Limits; prescribers must document prior treatment steps or request an exception with clinical justification.

    • Examples: ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, INVEGA SUSTENNA/TRINZA, REXULTI, VRAYLAR, ZYPREXA RELPREVV—many entries show ST and QL
    Note

    No explicit step therapy rules in this excerpt

    No explicit step therapy sequences or step order rules are provided in this extracted portion of the formulary; where ST appears on product lines, follow the product-level note or request an exception.

    • When no explicit sequence is present in the excerpt, rely on product Requirements/Limits or contact the plan for step details.
    Note

    Branded products may be subject to step edits

    Branded products in this segment may be subject to step edits even when explicit step rows are not shown; prescribers should check the product Requirements/Limits and submit PA/exception documentation as needed.

    • If unsure whether ST applies, include prior-treatment history in PA/exception requests.
    Note

    PA and QL are primary controls when step sequences absent

    This excerpt does not provide explicit step therapy sequences; prior authorization and quantity limits are the primary utilization controls—prescribers should follow PA/QL requirements or request an exception with supporting rationale.

    • When ST is not specified, focus on meeting PA and QL requirements shown for each product.
    Documentation Required

    Follow PA/QL when ST not specified

    Many product rows show PA and QL tags but do not list step therapy; prescribers must meet the PA and QL requirements listed or provide documentation when requesting an exception.

    • Examples: multiple products across genitourinary and GI sections show PA and QL without explicit ST sequencing
    Documentation Required

    PA and QL are enforceable where ST not listed

    This segment primarily shows PA, QL, OVM, B/D and other requirement tags on product rows; where ST is absent, PA and QL remain the enforceable provider actions.

    • Refer to the introduction pages for full definitions of these symbols when preparing PA/exception requests.
    Step Therapy

    Comply with ST for products explicitly marked 'ST'

    Some products are labeled 'ST' in the Requirements/Limits column (e.g., ROCKLATAN and ALCOHOL PREP PADS); prescribers must comply with step edits where indicated or submit supporting rationale for an exception.

    • ROCKLATAN = ST; ALCOHOL PREP PADS = ST (as shown in Requirements/Limits)
    Documentation Required

    Provide prescriber supporting statement; expect 72-hour standard decision

    When requesting a tiering or formulary exception, the prescriber's supporting statement is required; the plan generally makes a decision within 72 hours for standard requests and within 24 hours if expedited.

    • Prescribers should explain medical reasons why exception is necessary and submit supporting clinical documentation.
    • Standard decision timeframe: 72 hours; expedited decisions: 24 hours.
    Documentation Required

    Reference Formulary ID/Version/Effective Date on requests

    Use the formulary identifiers when submitting requests: Formulary ID 26449, Version 17, Effective Date 06/01/2026.

    • Include Formulary ID and Version/Effective Date on PA/exception correspondence when possible.
    Documentation Required

    Follow defined formulary symbols (PA, QL, ST, B/D, OVM)

    Follow the formulary symbol definitions when preparing claims and authorization requests—PA = prior authorization; QL = quantity limit; ST = step therapy; B/D and OVM meanings are in the introduction pages.

    • Refer to the introduction pages of the formulary for exact symbol definitions.
    Documentation Required

    Meet Requirements/Limits fields shown on product lines

    Formulary entries include Requirements/Limits fields such as PA, QL, ST, B/D and OVM; prescribers must satisfy or document adherence to those requirements when seeking coverage or submitting authorizations.

    • Provide medical necessity documentation when PA is required or when requesting QL overrides.
    Documentation Required

    Include supporting medical documentation for PA/QL/ST requests

    When a product is flagged with PA, QL, or ST, prescribers must include supporting documentation of medical necessity in the PA or exception request; the formulary notes these documentation expectations though specific forms are not included in this excerpt.

    • Include clinical rationale and prior-treatment history where applicable to support exceptions to PA/ST/QL.
    Denial Risk

    Adhere to PA/QL/ST on flagged prescriptions

    Prescriptions flagged with PA, QL(...), or ST require adherence to the listed prior authorization, quantity limits, or step therapy rules as specified in the formulary; failure to meet these may result in denial.

    • If a claim is submitted without required PA or exceeds QL, it may be denied or require an override.
    Billing Rule

    Respect specified quantity limits when prescribing/dispensing

    Quantity limits are specified for many products and must be respected in dispensing and claims (examples include dabigatran QL(180 EA per 90 days), ELIQUIS starter pack QL(148 EA per 365 days), and rivaroxaban suspension QL(2700 ML per 90 days)).

    • Verify QL values on the product line before authorizing fill quantities.
    Documentation Required

    Use product Requirements/Limits to prepare PA/exception submissions

    Formulary rows list drug name, strength, tier, and Requirements/Limits (e.g., QL or PA) which providers should use to support coverage decisions and when preparing PA/exception requests.

    • Use the listed Requirements/Limits as the source for PA/QL/ST compliance and documentation.
    Documentation Required

    Provide medical necessity documentation for PA/QL

    Where the formulary entry lists 'PA' and/or a QL, prescribers should provide documentation supporting medical necessity when submitting a prior authorization or exception request.

    • Include clinical notes showing prior therapy, response, or contraindications to preferred alternatives when relevant.
    Documentation Required

    Include clinical evidence with PA/QL requests (specifics per plan processes)

    Formulary entries include QL and PA flags but specific required documentation fields are not detailed in this excerpt; prescribers should follow plan instructions for PA submissions and include supportive medical evidence.

    • When in doubt, include relevant clinical history, diagnoses, and prior-treatment records with the PA request.
    Documentation Required

    Supply documentation supporting PA for products with PA/OVM

    Formulary product rows specify Requirements/Limits such as PA, QL, and OVM; providers should supply documentation supporting PA when required and follow the listed limits to avoid denials.

    • Examples: PROLASTIN‑C, REVCOVI, sapropterin entries list PA; include relevant clinical justification for these agents.
    Documentation Required

    Comply with product-specific Requirements/Limits (PA/QL/OVM/B/D)

    Formulary rows include assorted instructions (PA, QL, OVM, B/D, Prefilled Syringe notes); providers must meet these requirements when submitting for coverage or administrating therapy.

    • Check each product's Requirements/Limits field for any special handling or site-of-care indications.
    Billing Rule

    Respect QL values in dispensing and claims

    Quantity limit entries in the formulary (e.g., QL(1080 EA per 90 days), QL(360 EA per 90 days)) must be respected in dispensing claims; exceeding QL may trigger denial or require an override/PA.

    • Pharmacists should confirm allowed quantities prior to dispensing multi-month supplies.
    Denial Risk

    Denial risk if PA not obtained

    Failure to obtain required prior authorization may result in the plan not covering the drug; prescribers must secure PA or request an exception with supporting clinical rationale.

    • If PA is denied or not obtained, the claim may be denied and the member may be financially responsible.
    Documentation Required

    PA and QL indicators require compliance

    PA and QL indicators are present across many entries (e.g., VOQUEZNA, multiple anticonvulsant specialty products); prescribers must obtain PA and adhere to QLs where shown to avoid denial.

    • Examples: VOQUEZNA packs = QL + PA; multiple anticonvulsant formulations show PA and QL flags.
    Denial Risk

    PA + QL entries can trigger denial without compliance

    Products listed with both 'PA' and 'QL' may be denied if prior authorization is not obtained or if the requested quantity exceeds the QL; include justification when requesting overrides.

    • Example: LIBERVANT FILM shows QL(10 EA per 30 days); PA — requests exceeding this must be justified.
    Denial Risk

    Verify PA/OVM requirements to avoid denial

    Many formulary agents require prior authorization and other limits (OVM); failure to obtain PA may trigger coverage denial—prescribers should verify Requirements/Limits before prescribing.

    • Confirm PA/OVM requirements for oncology and specialty oral agents prior to initiating therapy.
    Denial Risk

    Denial risk if PA/QL/ST requirements not met

    Requests may be denied if the listed utilization controls (PA, QL, ST) are not met for specific products; prescribers should document compliance or provide medical rationale when requesting exceptions.

    • Include prior-treatment history and intolerance or contraindication evidence to support exception requests.
    Prior Authorization

    PA indicated for GLP‑1 receptor agonists

    Some GLP‑1 receptor agonists and other high-cost agents are annotated 'PA' in the Requirements/Limits field—prescribers must obtain prior authorization for these products (e.g., liraglutide, MOUNJARO, OZEMPIC, RYBELSUS).

    • Liraglutide injection = QL(27 ML per 90 days); PA
    • MOUNJARO, OZEMPIC, RYBELSUS entries show QL and PA
    Prior Authorization

    PA required for select concentrated insulin products

    Concentrated insulin coverage may be restricted—HUMULIN R U‑500 products list 'PA' in Requirements/Limits; prescribers must obtain prior authorization for these concentrated insulin formulations.

    • HUMULIN R U‑500 (Concentrated) Injection 500UNIT/ML = Requirements/Limits: PA
    Prior Authorization

    PA required for select hematology/oncology supportive agents

    Some hematology/oncology supportive agents are marked PA and may include OVM; prescribers must request prior authorization and follow any site-of-care or administration instructions.

    • Examples: FULPHILA, NEULASTA ONPRO, NEULASTA — Requirements/Limits = PA; OVM
    Prior Authorization

    Obtain PA for listed lipid/cardiovascular agents

    Drugs labeled 'PA' (e.g., NEXLETOL, NEXLIZET, PRALUENT, KERENDIA) require prior authorization; claims submitted without the required authorization may be denied or not covered.

    • PRALUENT injection: QL(2 ML per 28 days); PA
    • KERENDIA: QL(90 EA per 90 days); PA
    Prior Authorization

    PA is required where shown in Requirements/Limits

    Where entries include 'PA' in Requirements/Limits, coverage will require prior authorization; prescribers must secure approval to avoid denial.

    • Multiple specialty injectables and depot products in this section show PA in Requirements/Limits.
    Prior Authorization

    Confirm and obtain PA for PA‑flagged drugs

    Prior authorization is required for many formulary agents; claims submitted without required PA may be denied—prescribers should confirm PA needs and submit authorization requests before dispensing.

    • Check each product's Requirements/Limits for PA indicators prior to initiating therapy.
    Prior Authorization

    PA and QL apply to OTEZLA formulations

    Some products (e.g., OTEZLA formulations) are labeled with QL and PA; prescribers must obtain prior authorization and adhere to the QL for these agents.

    • OTEZLA tablet 20/30mg = QL(62 EA per 31 days); PA
    • OTEZLA XR 75mg = QL(31 EA per 31 days); PA
    Prior Authorization

    Obtain PA for listed specialty/genetic disorder agents

    Multiple products in this segment are listed with PA; prescribers must obtain prior authorization per the Requirements/Limits column before coverage will be provided.

    • Examples include genetic disorder agents, growth hormones, depot somatostatin analogs—many require PA.
    Step Therapy

    Document prior-step therapy or request exception for ST products

    Some products are explicitly marked 'ST' and require a prior step before coverage; prescribers should document prior use of preferred agents or request an exception with supporting clinical evidence.

    • When requesting exceptions to ST, include documentation that preferred drug trial failed or was not tolerated.
    Step Therapy

    ST applies to EXXUA and TRINTELLIX

    EXXUA and TRINTELLIX are examples of products marked 'ST'—prescribers must follow step therapy rules indicated in the formulary or submit an exception with rationale.

    • EXXUA Requirements/Limits = QL(...); ST
    • TRINTELLIX Requirements/Limits = QL(...); ST
    Step Therapy

    Step therapy flag on febuxostat requires prior-step evidence

    Some products include 'ST' in Requirements/Limits (e.g., febuxostat), indicating step therapy requirements apply; prescribers must show trial of preferred therapy or request an exception.

    • febuxostat entries show QL(...) and ST—document prior therapy as needed.
    Step Therapy

    RYTARY entries include ST — document prior steps or request exception

    Some RYTARY formulations list ST alongside QL; prescribers must follow step therapy requirements or provide supporting documentation for an exception.

    • RYTARY extended-release entries show QL and ST—include prior-treatment history when submitting PA/exception.
    Step Therapy

    ST applies to selected long‑acting injectables and antipsychotics

    Certain long-acting injectable antipsychotics and oral agents are designated 'ST' in Requirements/Limits; prescribers must demonstrate prior use of preferred agents or request an exception with clinical rationale.

    • Examples: ARISTADA, INVEGA SUSTENNA/TRINZA, ABILIFY ASIMTUFII, REXULTI — many show ST and QL

    Step Therapy Rules and Affected Products

    Coverage requirementSummary
    Step therapy (ST)
    Member must try specified preferred drugs before the plan will cover alternative non-preferred drugs; prescriber may request an exception with supporting medical rationale (see exception process).
    Drug / group exampleStep therapy / other requirements
    Selected specialty anticonvulsants (e.g., perampanel, spritam, other specialty formulations)
    Many anticonvulsant entries include PA and QL; some specialty anticonvulsants are flagged with utilization controls and may be subject to step or clinical review as indicated by PA or ST flags in the Requirements/Limits column.
    ProductFormulary indicator
    EXXUA (titration pack and extended-release strengths)
    Requirements/Limits include QL and 'ST' indicating step therapy applies (EXXUA TITRATION PACK: QL(32 EA per 14 days); ST; EXXUA tablets: QL(31 EA per 31 days); ST).
    ProductFormulary indicator
    febuxostat (40 mg, 80 mg)
    Requirements/Limits = QL(90 EA per 90 days); ST — 'ST' indicator present showing step therapy applies.
    ProductFormulary indicator
    RYTARY extended-release capsules (multiple strengths)
    Requirements/Limits list QL values (e.g., QL(300 EA per 30 days); QL(360 EA per 30 days)) and 'ST' — indicating step therapy may apply for certain formulations.
    Product examplesStep therapy indicator
    Long-acting injectable antipsychotics (e.g., ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, INVEGA SUSTENNA/TRINZA)
    Multiple LAI and oral antipsychotic entries show 'ST' in Requirements/Limits (examples include QL + ST for ABILIFY products, ARISTADA injections and INVEGA products), indicating step therapy applies.
    Class / examplesAuthorization note
    GLP-1 receptor agonists (e.g., liraglutide, MOUNJARO, OZEMPIC, RYBELSUS, TRULICITY)
    Multiple GLP-1 products are annotated with 'PA' in Requirements/Limits; prior authorization is required for coverage as noted in the formulary entries.
    ProductRequirements/Limits
    NEULASTA ONPRO, ZARXIO, FULPHILA (supportive hematology/oncology agents)
    Requirements/Limits include 'PA' and 'OVM' for these agents (e.g., FULPHILA = PA; OVM; NEULASTA ONPRO = PA; OVM), indicating prior authorization and order/override management apply.
    ObservationImplication
    No explicit step therapy sequences in this excerpt
    For many high-cost agents in these chunks the primary controls shown are PA and QL rather than detailed step therapy sequences; where 'PA' is listed, prior authorization is required.
    ObservationImplication
    Step therapy not specified in these sections
    These formulary segments primarily use prior authorization (PA) and quantity limits (QL) as utilization controls; explicit step (fail‑first) sequences are not listed here.
    NoteAction
    Some products elsewhere are designated 'ST'
    The formulary indicates certain products are marked 'ST' and will require prior step(s) as indicated on the specific product lines; consult the product row for exact step requirements.

    Per-Product Quantity Limits

    inv-133: pioglitazone example — 31 tablets per prescription
    pioglitazone (example)31 tablets per prescription (example quantity limit noted in formulary intro)
    ContextListed as an example in 'Are there any restrictions on my coverage?' section
    ImplicationMay be in addition to standard one-month/three-month supply rules
    inv-134: Linezolid suspension reconstituted 100mg/5ml — 1680 ML
    Linezolid suspension reconstituted 100mg/5mlQL(1680 ML per 28 days)
    Linezolid tablet 600mgQL(56 EA per 28 days)
    ReferenceFrom formulary drug listing entries for linezolid
    inv-135: Linezolid tablet 600mg — 56 EA
    Linezolid tablet 600mgQL(56 EA per 28 days)
    TierDrug Tier = 4
    Listing contextAppears alongside injection and suspension formulations
    inv-136: VOQUEZNA DUAL/TRIPLE PAK THERAPY PACK — 336 EA
    VOQUEZNA Dual/Triple Pak Therapy PackQL(336 EA per 90 days); PA
    FormulationDual and Triple pak therapy pack entries listed with same QL
    TierDrug Tier = 4
    inv-137: DIFICID (fidaxomicin) tablet 200mg — 20 EA
    DIFICID (fidaxomicin) tablet 200mgQL(20 EA per 10 days)
    Indication contextListed under antifungals/anti-infectives segment
    TierDrug Tier = 5
    inv-138: Anticonvulsant specialty formulations — multiple QLs and PA flags across entries
    Anticonvulsant specialty formulations (selected examples)Multiple QLs and PA flags across entries (e.g., brivaracetam, EPIDIOLEX, FINTEPLA, levetiracetam disintegrating tablets)
    ImplicationMany entries include both QL and PA; check per-product row for exact values
    ExamplesSee FYCOMPA, SPRITAM, LEVETIRACETAM entries for specific QLs
    inv-139: LIBERVANT FILM — 10
    LIBERVANT FILMQL(10 EA per 30 days); PA; NDS
    TierDrug Tier = 4
    NoteNDS flag present per formulary listing
    inv-140: VALTOCO (all strengths listed) — 10
    VALTOCO (all strengths listed)QL(10 EA per 30 days); PA; NDS
    FormulationsMultiple therapy pack strengths listed with same QL
    TierDrug Tier = 5
    inv-141: vigabatrin (packet/tablet 500mg) — 186
    vigabatrin (packet/tablet 500mg)QL(186 EA per 31 days); PA
    FormulationPacket and tablet entries both carry same QL
    TierDrug Tier = 5
    inv-142: lacosamide solution 10mg/ml — 3600
    lacosamide solution 10mg/mlQL(3600 ML per 90 days)
    lacosamide tabletsQL(180 EA per 90 days) for some tablet strengths
    TierDrug Tier = 4
    inv-143: memantine HCl titration pak — 98
    memantine HCl titration pakQL(98 EA per 365 days)
    Formulary segmentListed in antidementia / memantine entries
    TierDrug Tier = 3
    inv-144: AUVELITY — 62
    AUVELITY (extended release)QL(62 EA per 31 days); PA
    TierDrug Tier = 5
    ContextListed with QL and PA in antidepressant/other section
    inv-145: CRESEMBA CAPSULE 74.5MG — 175
    CRESEMBA capsule 74.5mgQL(175 EA per 31 days); PA
    CRESEMBA capsule 186mgQL(70 EA per 31 days); PA
    TierDrug Tier = 5
    inv-146: scopolamine patch 72 hour 1mg/3days — 30
    scopolamine patch 72 hour 1mg/3daysQL(30 EA per 90 days)
    aprepitant capsule therapy packPA; B/D indicated on some pack sizes
    ondansetronB/D flags on solution and ODT formulations
    inv-147: CRESEMBA CAPSULE 74.5MG — 175 (duplicate listing chunk)
    CRESEMBA capsule 74.5mg (duplicate entry)QL(175 EA per 31 days); PA
    NoteDuplicate listing appears in formulary excerpt
    TierDrug Tier = 5
    inv-148: CRESEMBA CAPSULE 186MG — 70
    CRESEMBA capsule 186mgQL(70 EA per 31 days); PA
    TierDrug Tier = 5
    ContextHigher-strength capsule has lower QL compared with 74.5mg
    inv-149: posaconazole dr tablet delayed release 100mg — 93
    posaconazole DR tablet delayed release 100mgQL(93 EA per 31 days); PA
    TierDrug Tier = 5
    Usage noteAntifungal with PA and a month-based QL
    inv-150: AIMOVIG INJECTION 140MG/ML — 3
    AIMOVIG injection 140mg/mlQL(3 ML per 84 days); PA
    AIMOVIG 70mg/mlQL(6 ML per 84 days); PA
    TierDrug Tier = 3
    inv-151: LORBRENA 25MG — QL(93 EA per 31 days)
    LORBRENA 25mgQL(93 EA per 31 days)
    ROZLYTREK 200mgQL(93 EA per 31 days); PA; OVM
    ContextExamples of oncology oral agents with per-31-day QLs
    inv-152: ROZLYTREK 200MG — QL(93 EA per 31 days)
    ROZLYTREK 200mgQL(93 EA per 31 days); PA; OVM
    TierDrug Tier = 5
    ImplicationOncology agent with QL and utilization controls
    inv-153: VENCLEXTA STARTING PACK — QL(84 EA per 365 days)
    VENCLEXTA starting packQL(84 EA per 365 days); PA; OVM
    VENCLEXTA tabletsPA; OVM for selected tablet strengths
    Formulary noteStarting packs and maintenance packs have separate QLs
    inv-154: PANRETIN GEL 0.1% — QL(60 GM per 30 days)
    PANRETIN gel 0.1%QL(60 GM per 30 days); PA
    IndicationTopical retinoid formulation listed with 30-day GM limit
    TierDrug Tier = 5
    inv-155: RYTARY CAPSULE EXTENDED RELEASE (selected strengths) — QL(300-360 EA per 30 days)
    RYTARY capsule extended release (selected strengths)QL(300-360 EA per 30 days) depending on strength; ST
    ST flagSome strengths include step therapy requirement alongside QL
    TierDrug Tier = 4
    inv-156: Selected formulary drugs — assorted QL examples across multiple entries
    Sample QL patternsExamples include QL(2.4 ML per 56 days); QL(1 EA per 28 days); QL(180 EA per 90 days)
    Selected productsAripiprazole LAIs, ARISTADA, ABILIFY ASIMTUFII show ML-based QLs and ST where noted
    Actionable noteCheck individual product row for exact QL and ST flags
    inv-157: DESCOVY TABLET — 31 EA
    DESCOVY tabletQL(31 EA per 31 days)
    TierDrug Tier = 5
    ContextMultiple emtricitabine/tenofovir formulations show 31-per-month QLs
    inv-158: emtricitabine/tenofovir disoproxil fumarate — 31 EA
    emtricitabine/tenofovir disoproxil fumarateQL(31 EA per 31 days)
    Multiple presentationsSeveral strengths/formulations listed with same 31-day QL
    TierVaries by product row
    inv-159: TRIUMEQ PD TABLET SOLUBLE — 180 EA
    TRIUMEQ PD tablet solubleQL(180 EA per 30 days)
    TRIUMEQ tabletQL(31 EA per 31 days) for standard tablet
    TierDrug Tier = 4 (PD soluble); Tier = 5 (tablet)
    inv-160: liraglutide injection 6mg/ml — 27 ML
    liraglutide injection 6mg/mlQL(27 ML per 90 days); PA
    MOUNJARO injection 10mg/0.5mlQL(2 ML per 28 days); PA
    OZEMPIC injection (2/4/8mg per 3ml)QL(3 ML per 28 days); PA
    inv-161: MOUNJARO INJECTION — 2 ML
    MOUNJARO injectionQL(2 ML per 28 days); PA
    TierDrug Tier = 3
    Formulary noteGLP-1 receptor agonists frequently carry PA and ML-based QLs
    inv-162: OZEMPIC INJECTION — 3 ML
    OZEMPIC injection formulationsQL(3 ML per 28 days); PA
    TierDrug Tier = 3
    NoteMultiple strengths share same ML-per-period QL
    inv-163: dabigatran etexilate capsule — QL(180 EA per 90 days)
    dabigatran etexilate capsuleQL(180 EA per 90 days)
    Use noteOral anticoagulant QL given per 90-day supply
    Formulary contextListed among anticoagulants with similar QL patterns
    inv-164: ELIQUIS STARTER PACK — QL(148 EA per 365 days)
    ELIQUIS starter pack tablet therapy pack 5mgQL(148 EA per 365 days)
    ELIQUIS soluble tablet entriesMultiple soluble tablet QLs shown separately (1164,1552,388 EA per 90 days)
    Formulary noteStarter pack has annual QL while maintenance tablets use 90-day QLs
    inv-165: rivaroxaban suspension reconstituted — QL(2700 ML per 90 days)
    rivaroxaban suspension reconstituted 1mg/mlQL(2700 ML per 90 days)
    Formulation noteLarge-volume suspension QL specified per 90 days
    Clinical implicationClaims exceeding this ML limit may require PA/override
    inv-166: eltrombopag olamine packet 25mg — QL(186 EA per 31 days)
    eltrombopag olamine packet 25mgQL(186 EA per 31 days)
    eltrombopag tablet strengthsOther tablet strengths carry separate QLs and PA flags
    TierDrug Tier = 5
    inv-167: VOYDEYA TABLET / THERAPY PACK — QL(180 EA per 30 days)
    VOYDEYA tablet / therapy pack 100mgQL(180 EA per 30 days); PA
    Therapy pack noteTherapy packs and unit tablets share the same 30-day QL
    TierDrug Tier = 5
    inv-168: ELIQUIS soluble tablet entries — assorted QLs
    ELIQUIS tablet soluble 0.5mg (various entries)QL(1164 EA per 90 days); QL(1552 EA per 90 days); QL(388 EA per 90 days)
    Dose mappingDifferent dose-conversion rules reflected in multiple QLs for same formulation
    ActionVerify exact pack/strength row when adjudicating claims
    inv-169: Examples across formulary — common QL patterns
    Common QL examples across formularyQL(180 EA per 90 days); QL(360 EA per 90 days); QL(90 EA per 90 days); QL(2 ML per 28 days); QL(1350 ML per 90 days)
    ImplicationThese patterns recur for chronic oral meds, extended supplies, injectables, and large-volume solutions
    Provider noteAdjudicate against the per-product QL shown in the formulary row
    inv-170: ezetimibe/simvastatin tablet — QL(90 EA per 90 days)
    ezetimibe/simvastatin tabletQL(90 EA per 90 days)
    ezetimibe tablet 10mgQL(90 EA per 90 days)
    ContextStandard 90-day QL applied to lipid agents
    inv-171: ezetimibe tablet 10mg — QL(90 EA per 90 days)
    ezetimibe tablet 10mgQL(90 EA per 90 days)
    TierDrug Tier = 3
    Formulary noteMatches common lipid-agent QL pattern
    inv-172: PRALUENT INJECTION — QL(2 ML per 28 days)
    PRALUENT injection 150mg/ML, 75mg/MLQL(2 ML per 28 days); PA
    TierDrug Tier = 3
    Usage noteML-based QL typical for PCSK9 inhibitors
    inv-173: omega-3-acid ethyl esters — QL(360 EA per 90 days)
    omega-3-acid ethyl estersQL(360 EA per 90 days)
    TierDrug Tier = 3
    ContextExample of 90-day EA-based QL for nutraceutical agent
    inv-174: RYTARY and stimulant examples — assorted QLs
    amphetamine/dextroamphetamine ER capsulesQL(180 EA per 90 days)
    dexmethylphenidate tabletsQL(60 EA per 30 days)
    betaseron injectionQL(14 EA per 28 days); PA
    inv-175: dexmethylphenidate tablets — 60 EA
    dexmethylphenidate tabletsQL(60 EA per 30 days)
    ER capsule variantsOther ER capsules show 30-day or 90-day QLs depending on formulation
    TierDrug Tier = varies
    inv-176: betaseron injection — QL(14 EA per 28 days)
    betaseron injectionQL(14 EA per 28 days); PA
    dimethyl fumarate starterpackQL(120 EA per 365 days); PA
    fingolimod capsuleQL(31 EA per 31 days); PA
    inv-177: dimethyl fumarate starterpack — QL(120 EA per 365 days)
    dimethyl fumarate starterpackQL(120 EA per 365 days); PA
    maintenance capsQL(62 EA per 31 days); PA for some formulations
    TierStarter pack and maintenance differ in QL cadence
    inv-178: fingolimod hydrochloride capsule — QL(31 EA per 31 days)
    fingolimod hydrochloride capsule 0.5mgQL(31 EA per 31 days); PA
    TierDrug Tier = 5
    Formulary noteMS agents commonly have 31-day QLs and PA
    inv-179: ADBRY INJECTION 300MG/2ML — QL(6 ML per 28 days)
    ADBRY injection 300mg/2mlQL(6 ML per 28 days); PA
    ADBRY 150mg/mlQL(8 ML per 28 days); PA
    TierDrug Tier = 5
    inv-180: OTEZLA TABLET — QL(62 EA per 31 days)
    OTEZLA tabletQL(62 EA per 31 days); PA
    OTEZLA XR 75mgQL(31 EA per 31 days); PA
    Initiation packsTherapy packs have specific QLs (28 EA per 28 days)
    inv-181: calcipotriene cream/solution — QLs for topical formulations
    calcipotriene cream 0.005%QL(360 GM per 90 days); PA
    calcipotriene solution 0.005%QL(180 ML per 90 days); PA
    clindamycin phosphate topical formsQLs vary (225 ML/GM per 90 days etc.)
    inv-182: OTEZLA XR 75MG — QL(31 EA per 31 days)
    calcipotriene solution 0.005%QL(180 ML per 90 days); PA
    Formulation noteLiquid topical formulations use ML-based QLs
    TierDrug Tier = 3
    inv-183: clindamycin phosphate topical — 225 ML/GM per 90 days
    clindamycin phosphate topical (various)QL(225 ML/GM per 90 days) depending on formulation
    mupirocin ointment 2%QL(90 GM per 90 days)
    ContextTopical anti-infectives use GM/ML limits per 90 days
    inv-184: mupirocin ointment 2% — 90 GM per 90 days
    mupirocin ointment 2%QL(90 GM per 90 days)
    TierDrug Tier = 3
    Provider noteTopical antibiotic limited to 90 GM per 90 days
    inv-185: tolvaptan tablet — 124 EA per 31 days
    tolvaptan tabletQL(124 EA per 31 days); PA
    sevelamer carbonate 800mgQL(1620 EA per 90 days)
    LOKELMA packet 5GMQL(270 EA per 90 days)
    inv-186: sevelamer carbonate tablet — 1620 EA per 90 days
    sevelamer carbonate tablet 800mgQL(1620 EA per 90 days)
    LOKELMA packet 5GMQL(270 EA per 90 days)
    ContextGI/potassium binder agent QLs given per 90 days
    inv-187: LOKELMA PACKET 5GM — 270 EA per 90 days
    LOKELMA packet 5GMQL(270 EA per 90 days)
    Alternate packet sizeLOKELMA packet 10GM listed with QL(94 EA per 90 days)
    Provider noteCheck packet size when adjudicating claims
    inv-188: LINZESS capsule — 90 EA per 90 days
    LINZESS capsuleQL(90 EA per 90 days)
    XIFAXAN 550mgQL(93 EA per 31 days); PA
    MOVANTIKQL(180 EA per 90 days); PA
    inv-189: XIFAXAN 550MG — 93 EA per 31 days
    XIFAXAN 550mgQL(93 EA per 31 days)
    TierDrug Tier = 5
    Coverage noteShort-course antibiotic packs have 31-day QLs
    inv-190: pantoprazole sodium tablet — QL(180 EA per 90 days)
    pantoprazole sodium DR tablet 20/40mgQL(180 EA per 90 days)
    l-glutamine packet 5gmQL(180 EA per 30 days); PA
    nitisinone capsuleQL(24 EA per 90 days); PA
    inv-191: l-glutamine packet 5gm — QL(180 EA per 30 days)
    l-glutamine packet 5gmQL(180 EA per 30 days); PA
    PROLASTIN-C injectionPA
    REVCOVI injectionPA
    inv-192: nitisinone capsule — QL(24 EA per 90 days)
    nitisinone capsuleQL(24 EA per 90 days); PA
    sapropterin dihydrochloridePA (packet/tablet entries)
    Provider noteGenetic disorder treatments commonly carry PA and specific QLs
    inv-193: fesoterodine and other urinary agents — various QL values
    fesoterodine; GEMTESA; MYRBETRIQ; oxybutynin; solifenacin; tolterodineVarious QL values (e.g., QL(90 EA per 90 days), QL(180 EA per 90 days), QL(31 EA per 31 days))
    Formulary noteAntimuscarinic/urinary agents show multiple QL cadences
    ActionVerify per-strength QL when adjudicating
    inv-194: testosterone pump gel — QL(450 GM per 90 days)
    testosterone pump gel 1.62%QL(450 GM per 90 days)
    etonogestrel/ethinyl estradiol ring (e.g., eluryng)QL(3 EA per 84 days)
    DEPO-SUBQ PROVERA 104 injectionQL(0.65 ML per 90 days)
    inv-195: etonogestrel/ethinyl estradiol ring — QL(3 EA per 84 days)
    etonogestrel/ethinyl estradiol ring (various)QL(3 EA per 84 days)
    Formulary noteContraceptive ring QL aligns with 84-day dispensing
    Provider actionDispense per pack QL to avoid claims denial
    inv-196: DEPO-SUBQ PROVERA injection — QL(0.65 ML per 90 days)
    DEPO-SUBQ PROVERA 104 injection 104mg/0.65mlQL(0.65 ML per 90 days)
    TierDrug Tier = listed under contraceptives/hormonal agents
    Coverage noteInjectable contraceptive QL given per 90 days
    inv-197: icatibant acetate injection — 27 ML
    icatibant acetate injection 30mg/3mlQL(27 ML per 30 days); PA
    Angioedema agents noteListed with ML-per-30-day QL
    Denial riskClaims exceeding QL may be denied or require PA
    inv-198: COSENTYX injection — 8 ML
    COSENTYX injection 150mg/mlQL(8 ML per 28 days); PA
    Alternate strengths75mg presentation QL(4 ML per 28 days)
    Formulary noteBiologics often use ML-based QLs and require PA
    inv-199: RINVOQ LQ SOLUTION — 360 ML
    RINVOQ LQ solution 1mg/mlQL(360 ML per 30 days); PA
    RINVOQ tablet ERSeparate QLs (EA per 31 days) exist for tablet forms
    Provider noteSolution formulations use ML QLs and require PA
    inv-200: SKYRIZI injection — 2.4 ML
    SKYRIZI injection 180mg/1.2ml, 360mg/2.4mlQL(2.4 ML per 56 days); PA
    SKYRIZI larger vialQL(20 ML per 28 days) listed for some presentations
    Formulary noteML-per-period QLs vary by presentation
    inv-201: STELARA injection — 208 ML
    STELARA injection 130mg/26mlQL(208 ML per 365 days); PA
    USTEKINUMAB 130mg/26mlQL(208 ML per 365 days); PA
    Provider noteAnnual ML QLs used for some large-volume biologics
    inv-202: MESALAMINE DR CAPSULE 400MG — QL(1080 EA per 90 days)
    MESALAMINE DR capsule 400mgQL(1080 EA per 90 days)
    mesalamine DR tablet 1.2gmQL(360 EA per 90 days)
    mesalamine DR tablet 800mgQL(540 EA per 90 days)
    inv-203: mesalamine dr tablet 1.2gm — QL(360 EA per 90 days)
    mesalamine dr tablet 1.2gQL(360 EA per 90 days)
    mesalamine enema 4gmQL(5400 ML per 90 days)
    mesalamine kitQL(5400 EA per 90 days)
    inv-204: RESTASIS MULTIDOSE EMULSION — QL(180 ML per 90 days)
    RESTASIS multidose emulsion 0.05%QL(180 ML per 90 days)
    XIIDRA solutionQL(180 EA per 90 days)
    TYRVAYA solutionQL(8.4 ML per 30 days)
    inv-205: TYRVAYA SOLUTION — QL(8.4 ML per 30 days)
    TYRVAYA solution 0.03mg/actQL(8.4 ML per 30 days)
    Ophthalmic ML/EA patternsMultiple ophthalmic products list ML or EA QLs per 30/90 days
    Provider actionConfirm QL when dispensing ophthalmic solutions
    inv-206: Examples across formulary — common QL patterns for respiratory and emergency meds
    montelukast sodium tablet 10mgQL(90 EA per 90 days)
    SPIRIVA HandiHaler capsule 18mcgQL(90 EA per 90 days)
    EPINEPHRINE injection (auto-injectors)QL(6 EA per 90 days)

    Infusion/Administration and Site-Specific Notes

    Note

    Formulary Symbols and Term Definitions

    Formulary Background and Scope

    The formulary groups medications by therapeutic category and lists each product with a formulary tier and any Requirements/Limits such as PA (prior authorization) and explicit QL (quantity limits expressed as units per time period). These flags are used as the primary utilization-management controls in this document segment and prescribers should follow the listed PA/QL/ST instructions when seeking coverage.

    Biosimilar Substitution and Interchangeable Products

    Note